{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:28:01Z","timestamp":1773916081641,"version":"3.50.1"},"reference-count":46,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.3892\/ijo.2013.1954","type":"journal-article","created":{"date-parts":[[2013,5,24]],"date-time":"2013-05-24T08:35:18Z","timestamp":1369384518000},"page":"365-374","source":"Crossref","is-referenced-by-count":27,"title":["Induction of retinol-binding protein 4 and placenta-specific 8 expression in human prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by osteoprotegerin"],"prefix":"10.3892","volume":"43","author":[{"given":"HISANORI","family":"UEHARA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TETSUYUKI","family":"TAKAHASHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KEISUKE","family":"IZUMI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,5,24]]},"reference":[{"key":"key20180107183137_b1-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3322\/caac.20121","article-title":"Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths","volume":"61","author":"Siegel","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"key20180107183137_b2-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"key":"key20180107183137_b3-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"key20180107183137_b4-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"key20180107183137_b5-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/cncr.11127","article-title":"Bone markers in the management of patients with skeletal metastases","volume":"97","author":"Demers","year":"2003","journal-title":"Cancer"},{"key":"key20180107183137_b6-ijo-43-02-0365","first-page":"41","article-title":"Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption","volume":"13","author":"Percival","year":"1987","journal-title":"Eur J Surg Oncol"},{"key":"key20180107183137_b7-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.urology.2012.04.007","article-title":"Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices","volume":"80","author":"Freedland","year":"2012","journal-title":"Urology"},{"key":"key20180107183137_b8-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/jnci\/djs263","article-title":"Effects of bone-targeted agents on cancer progression and mortality","volume":"104","author":"Coleman","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"key20180107183137_b9-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/8756-3282(91)90057-P","article-title":"Mechanisms of osteolytic bone destruction","volume":"12","author":"Mundy","year":"1991","journal-title":"Bone"},{"key":"key20180107183137_b10-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"key20180107183137_b11-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"key20180107183137_b12-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"key20180107183137_b13-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","article-title":"Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone","volume":"107","author":"Zhang","year":"2001","journal-title":"J Clin Invest"},{"key":"key20180107183137_b14-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1158\/0008-5472.CAN-04-2033","article-title":"Osteoprotegerin in prostate cancer bone metastasis","volume":"65","author":"Corey","year":"2005","journal-title":"Cancer Res"},{"key":"key20180107183137_b15-ijo-43-02-0365","first-page":"7883","article-title":"Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res"},{"key":"key20180107183137_b16-ijo-43-02-0365","first-page":"912","article-title":"Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand\/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells","volume":"63","author":"Shipman","year":"2003","journal-title":"Cancer Res"},{"key":"key20180107183137_b17-ijo-43-02-0365","first-page":"1619","article-title":"Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells","volume":"62","author":"Holen","year":"2002","journal-title":"Cancer Res"},{"key":"key20180107183137_b18-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10456-008-9127-z","article-title":"Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function","volume":"12","author":"McGonigle","year":"2009","journal-title":"Angiogenesis"},{"key":"key20180107183137_b19-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","article-title":"Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis","volume":"39","author":"Peddi","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"key20180107183137_b20-ijo-43-02-0365","first-page":"89","article-title":"Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors","volume":"6","author":"Brown-Glaberman","year":"2012","journal-title":"Biologics"},{"key":"key20180107183137_b21-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/jnci\/95.6.458","article-title":"Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases","volume":"95","author":"Uehara","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"key20180107183137_b22-ijo-43-02-0365","article-title":"Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial","volume-title":"Int J Clin Oncol","author":"Uemura","year":"2012"},{"key":"key20180107183137_b23-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"key20180107183137_b24-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180107183137_b25-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180107183137_b26-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180107183137_b27-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"key20180107183137_b28-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejca.2012.07.016","article-title":"Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis","volume":"49","author":"Ford","year":"2013","journal-title":"Eur J Cancer"},{"key":"key20180107183137_b29-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180107183137_b30-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/35094009","article-title":"The development of androgen-independent prostate cancer","volume":"1","author":"Feldman","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"key20180107183137_b31-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.canlet.2006.03.025","article-title":"Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3","volume":"247","author":"Ting","year":"2007","journal-title":"Cancer Lett"},{"key":"key20180107183137_b32-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1038\/sj.onc.1207461","article-title":"Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells","volume":"23","author":"Bao","year":"2004","journal-title":"Oncogene"},{"key":"key20180107183137_b33-ijo-43-02-0365","first-page":"1845","article-title":"Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells","volume":"18","author":"Arah","year":"1998","journal-title":"Anticancer Res"},{"key":"key20180107183137_b34-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/0008-5472.CAN-05-3119","article-title":"Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically","volume":"66","author":"Fisher","year":"2006","journal-title":"Cancer Res"},{"key":"key20180107183137_b35-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj3180001","article-title":"The lipocalin protein family: structure and function","volume":"318","author":"Flower","year":"1996","journal-title":"Biochem J"},{"key":"key20180107183137_b36-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0167-4838(00)00150-3","article-title":"Plasma retinol binding protein: structure and function of the prototypic lipocalin","volume":"1482","author":"Newcomer","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"key20180107183137_b37-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/S0021-9258(18)46017-6","article-title":"Retinoids and retinoid-binding protein expression in rat adipocytes","volume":"267","author":"Tsutsumi","year":"1992","journal-title":"J Biol Chem"},{"key":"key20180107183137_b38-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.2337\/db06-1647","article-title":"Effects of genetic variation in the human retinol binding protein-4 gene (RBP4) on insulin resistance and fat depot-specific mRNA expression","volume":"56","author":"Kovacs","year":"2007","journal-title":"Diabetes"},{"key":"key20180107183137_b39-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1056\/NEJMoa054862","article-title":"Retinol-binding protein 4 and insulin resistance in lean, obese and diabetic subjects","volume":"354","author":"Graham","year":"2006","journal-title":"N Engl J Med"},{"key":"key20180107183137_b40-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature03711","article-title":"Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes","volume":"436","author":"Yang","year":"2005","journal-title":"Nature"},{"key":"key20180107183137_b41-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/35055575","article-title":"Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver","volume":"409","author":"Abel","year":"2001","journal-title":"Nature"},{"key":"key20180107183137_b42-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"628787","DOI":"10.1155\/2011\/628787","article-title":"The application of a three-step proteome analysis for identification of new biomarkers of pancreatic cancer","volume":"2011","author":"Abulaizi","year":"2011","journal-title":"Int J Proteomics"},{"key":"key20180107183137_b43-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1200\/JCO.2007.13.5392","article-title":"Panel of serum biomarkers for the diagnosis of lung cancer","volume":"25","author":"Patz","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180107183137_b44-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/1568009611309010080","article-title":"Apoptosis suppression by candidate oncogene PLAC8 is reversed in other cell types","volume":"13","author":"Mourtada-Maarabouni","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"key20180107183137_b45-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1128\/MCB.26.9.3401-3413.2006","article-title":"The negative c-Myc target onzin affects proliferation and apoptosis via its obligate interaction with phospholipid scramblase 1","volume":"26","author":"Li","year":"2006","journal-title":"Mol Cell Biol"},{"key":"key20180107183137_b46-ijo-43-02-0365","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1038\/sj.onc.1208897","article-title":"Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway","volume":"24","author":"Rogulski","year":"2005","journal-title":"Oncogene"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2013.1954\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T20:42:02Z","timestamp":1645562522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2013.1954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,24]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,5,24]]},"published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.3892\/ijo.2013.1954"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2013.1954","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,24]]}}}